<DOC>
	<DOC>NCT01658202</DOC>
	<brief_summary>The purpose of this study is to compare the relative bioavailability of nicotine following single application of a new transdermal formulation to that of a reference formulation. 4 single 24hour applications separated by 48hour intervals.</brief_summary>
	<brief_title>Nicotine Patch Bioequivalence Study</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy subject aged 18 to 45 years (inclusive) Current Smoker of &gt;or = 5 and &lt; or = 15 cigarettes/day Fagerstr√∂m score &lt; or =5 at selection Absence of any clinically significant abnormal finding at physical, vital sign, Electrocardiogram ECG, biological examinations in the investigator's opinion. Presence of any significant medical finding or significant history (in particular any cardiovascular disease, severe renal or hepatic insufficiency, current gastric or duodenal ulcer) that may impact the safety, the interpretation of the results and/or the participation of the subject in the study according to the opinion of the investigator Any visible skin disorder, abnormal skin pigmentation or dermatologic disease liable to interfere with use or assessment of transdermal patch</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Smoking cessation</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Tobacco Use Disorder</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>